Clinical Trials Logo
  1. Home
  2. Acute Myeloid Leukemia, Adult
  3. NCT05988047
  4. Details
NCT05988047 Clinical Trial

Analysis of CMTM6 Expression in Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia, Adult Clinical Trial

Official title:
Analysis of CMTM6 Expression in Patients With Acute Myeloid Leukemia

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT05988047
Other study ID # CMTM6_AML
Secondary ID
Status Completed
Phase
First received
Last updated
Start date May 1, 2020
Est. completion date May 1, 2024

Study information
Verified date May 2024
Source University of Freiburg
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

In this study, we aim to investigate the expression of CKLF like MARVEL transmembrane domain containing 6 (CMTM6) in leukemia cells of patients with acute myeloid leukemia (AML). We will use peripheral blood samples and assess CMTM6 expression by flow cytometry and Western Blot.

Recruitment information / eligibility
Status Completed
Enrollment 150
Est. completion date May 1, 2024
Est. primary completion date May 1, 2024
Accepts healthy volunteers
Gender All
Age group 18 Years to 99 Years
Eligibility Inclusion Criteria: - age = 18 years - primary diagnosis of acute myeloid leukemia - diagnosis results available - written informed consent - ability to understand the nature of the study and the study related procedures and to comply with them Exclusion Criteria: - age < 18 years - lack of informed consent

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
Germany Medical Center- University of Freiburg Freiburg CA

Sponsors (1)
Lead Sponsor Collaborator
University of Freiburg

Country where clinical trial is conducted

Germany, 

Outcome
Type Measure Description Time frame Safety issue
Primary CMTM6 expression (FC) CMTM6 expression on blasts/monocytes will be measured by flow cytometry At primary diagnosis
Primary T cell activation (FC) T cell activation and cytokine production will be measured by flow cytometry At primary diagnosis
Secondary CMTM6 expression (WB) CMTM6 expression on blasts/monocytes will be measured by Western blot At primary diagnosis
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05133882 - A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML Phase 1/Phase 2
Active, not recruiting NCT05601726 - First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients Phase 1
Recruiting NCT06200441 - Correlation of Serum Gasdermin-D and NLRP-3 Inflammasome Levels With GVHD Biomarkers and Endothelial Damage Markers in Graft-Versus-Host Disease
Recruiting NCT04050280 - CLAG-GO for Patients With Persistent, Relapsed or Refractory AML Phase 2
Recruiting NCT06449482 - Selinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not Eligible for Intense Chemotherapy Phase 1/Phase 2
Not yet recruiting NCT06252584 - Multi-peptide Vaccination Adjuvanted With XS15 in Acute Myeloid Leukemia Patients Phase 1
Terminated NCT03951961 - Midostaurin in MRD (Minimal Residual Disease) Positive Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation Phase 2
Enrolling by invitation NCT03902665 - Up-front Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients Aged 65-75 Phase 2
Not yet recruiting NCT06285136 - Safety and Efficacy of Venetoclax Combination With Decitabine(DEC3-VEN) in the Treatment of AML in the Adult Phase 2/Phase 3
Recruiting NCT05127798 - RWE of 1st Line Treatment in Adults With AML From 18 to 70 Years Old.
Recruiting NCT05906914 - Cladribine Plus Homoharringtonine and Cytarabine Regimen (CHA) for de Novo Acute Myeloid Leukemia Phase 2
Not yet recruiting NCT06199557 - A Study to Investigate Treatment of HU and VPA, or 6-MP and VPA in Unfit AML/HR-MDS Patients Phase 1/Phase 2
Recruiting NCT04752527 - Individualized Induction Therapy for Non-elderly Acute Myeloid Leukemia Patients With Adverse Risk Features Phase 2
Recruiting NCT03766126 - Lentivirally Redirected CD123 Autologous T Cells in AML Phase 1
Recruiting NCT05674539 - Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome Phase 3
Enrolling by invitation NCT02985372 - Decitabine in Combination With Low-dose Cytarabine in Elderly Patients With Acute Myeloid Leukemia Phase 3
Recruiting NCT05703126 - Clinical and Diagnostic Significance of Endothelial Dysfunction and Myocardial Contractility in Patients With AML N/A
Recruiting NCT04240600 - Effect of a Hyperproteic Hyperenergetic Enteral Formula on Body Composition and VEGF in AML During Hospital Stay N/A
Terminated NCT04425655 - Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia. Phase 2
Recruiting NCT04454580 - Hypomethylating Agents and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Not Eligible for Intensive Chemotherapy